BioCorRx Statistics
Total Valuation
BioCorRx has a market cap or net worth of $7.02 million. The enterprise value is $13.04 million.
| Market Cap | 7.02M |
| Enterprise Value | 13.04M |
Important Dates
The last earnings date was Wednesday, March 29, 2023.
| Earnings Date | Mar 29, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
BioCorRx has 9.61 million shares outstanding. The number of shares has increased by 13.13% in one year.
| Shares Outstanding | 9.61M |
| Shares Change (YoY) | +13.13% |
| Shares Change (QoQ) | +1.53% |
| Owned by Insiders (%) | 61.88% |
| Owned by Institutions (%) | n/a |
| Float | 3.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 134.08 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 249.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.02
| Current Ratio | 0.02 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.51 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -1,258.19% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $17,446 |
| Profits Per Employee | -$1.33M |
| Employee Count | 3 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3,331 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.17% in the last 52 weeks. The beta is 0.85, so BioCorRx's price volatility has been lower than the market average.
| Beta (1Y) | 0.85 |
| 52-Week Price Change | -59.17% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 1.16 |
| Relative Strength Index (RSI) | 37.33 |
| Average Volume (30 Days) | 942 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioCorRx had revenue of $52,338 and -$3.99 million in losses. Loss per share was -$0.46.
| Revenue | 52,338 |
| Gross Profit | -96,863 |
| Operating Income | -3.70M |
| Pretax Income | -4.00M |
| Net Income | -3.99M |
| EBITDA | -2.95M |
| EBIT | -3.15M |
| Loss Per Share | -$0.46 |
Balance Sheet
The company has $101,080 in cash and $6.12 million in debt, giving a net cash position of -$6.02 million or -$0.63 per share.
| Cash & Cash Equivalents | 101,080 |
| Total Debt | 6.12M |
| Net Cash | -6.02M |
| Net Cash Per Share | -$0.63 |
| Equity / Book Value | -10.74M |
| Book Value Per Share | -1.12 |
| Working Capital | -7.02M |
Cash Flow
| Operating Cash Flow | -1.80M |
| Capital Expenditures | n/a |
| Free Cash Flow | -1.80M |
| FCF Per Share | -$0.21 |
Margins
Gross margin is -185.07%, with operating and profit margins of -7,069.76% and -7,631.24%.
| Gross Margin | -185.07% |
| Operating Margin | -7,069.76% |
| Pretax Margin | -7,637.60% |
| Profit Margin | -7,631.24% |
| EBITDA Margin | -5,645.77% |
| EBIT Margin | -6,020.83% |
| FCF Margin | -3,430.77% |
Dividends & Yields
BioCorRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.13% |
| Shareholder Yield | -13.13% |
| Earnings Yield | -56.92% |
| FCF Yield | -25.59% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 22, 2019. It was a reverse split with a ratio of 1:100.
| Last Split Date | Jan 22, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
BioCorRx has an Altman Z-Score of -408.65 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -408.65 |
| Piotroski F-Score | 1 |